

1 **THE FEASIBILITY OF ONLINE VIDEO CALLING TO ENGAGE PATIENTS WITH**
2 **CYSTIC FIBROSIS IN EXERCISE TRAINING**

3 Owen W Tomlinson^{1,2}, James Shelley^{1,3,4}, Jayne Trott^{1,4}, Ben Bowhay^{1,4}, Rohan Chauhan⁵, &
4 Christopher D Sheldon^{1*}

5 1. Department of Respiratory Medicine, Royal Devon and Exeter NHS Foundation Trust
6 Hospital, Barrack Road, Exeter, EX2 5DW, United Kingdom.

7 2. Children's Health and Exercise Research Centre, Sport and Health Science, University
8 of Exeter, Heavitree Road, Exeter, EX1 2LU, United Kingdom.

9 3. Physical Activity Exchange, Research Institute for Sport and Exercise Sciences,
10 Liverpool John Moores University, Liverpool, L3 3AF, United Kingdom.

11 4. Department of Physiotherapy, Royal Devon and Exeter NHS Foundation Trust
12 Hospital, Barrack Road, Exeter, EX2 5DW, United Kingdom.

13 5. Research and Development Directorate, Noy Scott House, Royal Devon and Exeter
14 NHS Foundation Trust Hospital, Barrack Road, Exeter, EX2 5DW, United Kingdom.

15

16 **RUNNING TITLE:** Using Skype to deliver exercise in cystic fibrosis

17

18 ***Corresponding Author**

19 Dr Christopher Sheldon

20 Department of Respiratory Medicine,

21 Royal Devon and Exeter NHS Foundation Trust Hospital,

22 Barrack Road, Exeter, EX2 5DW, UNITED KINGDOM

23 chris.sheldon1@nhs.net

24

25 **CONFLICT OF INTEREST**

26 The authors declare no conflict of interest.

27 **ABSTRACT**

28 *Introduction:* Physical activity (PA), including structured exercise is an essential component
29 in the management of cystic fibrosis (CF). The use of telehealth such as video-calling may be
30 a useful method for the delivery of exercise and PA interventions, though the feasibility of this
31 remains unknown.

32 *Methods:* Nine patients with CF (three female, six male, 30.9 ± 8.7 years) volunteered to
33 participate. Participants completed an 8-week exercise training intervention conducted via
34 Skype, using personalised exercises, with all sessions supervised by an exercise therapist.
35 Feasibility was assessed by demand, implementation, practicality and acceptability. Changes
36 in anthropometric, pulmonary, PA and quality of life (QoL) variables were also assessed.

37 *Results:* Two male participants withdrew from the study, citing lack of available time.
38 Remaining participants found use of Skype useful, with a mean satisfaction rating of 9/10, and
39 three participants requesting to continue the sessions beyond the duration of the study. Mean
40 compliance with sessions was 68%, with mean duration of sessions being 20 minutes. A total
41 of 25% of calls suffered from technical issues such as video or audio lags. Anthropometric,
42 pulmonary, PA and QoL variables remained unchanged over the course of the study period.

43 *Discussion:* The use of Skype to deliver an exercise intervention to patients with CF was found
44 to be technologically feasible, and acceptable among participants. Findings have implications
45 for clinical practice and could allow care teams to engage patients remotely in exercise. Further
46 research is required to assess the efficacy of this modality on increasing PA and associated
47 health outcomes.

48

49 **KEYWORDS:** exercise, Skype, intervention, personalised training, telehealth, acceptability

50

51

52 **1. INTRODUCTION**

53 It is well established that physical activity (PA) – which includes structured exercise – is
54 beneficial for patients with cystic fibrosis (CF), with increased PA being associated with higher
55 levels of aerobic fitness (1) and slower rates of decline in lung function (2). Patients are
56 therefore recommended to remain physically active and exercise frequently, with global PA
57 guidelines of 150 minutes of moderate-vigorous PA (MVPA) per week for adults, and 60
58 minutes of MVPA daily for children also being appropriate for patients with CF (3). However,
59 adherence rates to treatment (including exercise) are variable (4) and it has subsequently been
60 suggested that supervision of exercise, and its subsequent incorporation into the home
61 environment, could improve adherence (5).

62

63 Telehealth technologies, including video-calling software such as Skype, self-care and
64 monitoring applications can potentially change how patients with CF engage with healthcare
65 services and reduce burden of care (6), improve monitoring (7) and potentially reduce costs
66 associated with healthcare delivery (8). Furthermore, factors that may negatively affect health
67 outcomes, such as risk of cross-infection (9) could potentially be overcome by the use of
68 telehealth systems.

69

70 Previous research suggests that patients with CF are willing to adopt and utilise such telehealth
71 technology (10), and that use of an online platform to engage patients in PA is feasible and
72 acceptable (11). Furthermore it feasible for both patients and practitioners to assess exercise
73 capacity remotely (12). Whilst this data provides evidence for the feasibility of remote
74 monitoring of PA and exercise capacity, the feasibility of delivering a supervised exercise
75 intervention is yet to be explored.

76

77 Supervised exercise training is effective in improving lung function and exercise capacity in
78 patients with CF (13). However, the gym- and hospital-based nature of these interventions can
79 burden patients with increased travel and parking costs, gym membership fees and exposure to
80 cross-infection risks through regular hospital visits. Home-based interventions may also
81 positively affect lung function in patients with CF (14) and therefore warrant further
82 investigation and implementation.

83

84 It is currently unclear whether implementing supervised, online, exercise sessions using
85 telehealth is feasible or acceptable among patients with CF. Therefore, this study sought to
86 assess the feasibility of utilising an online video-calling platform to engage patients with CF in
87 a personalised exercise regimen. This was primarily assessed by demand, implementation,
88 practicality and acceptability of the intervention; and secondly by identifying issues associated
89 with the online delivery of the intervention.

90

91 **2. METHODS**

92 *2.1. Study Population*

93 Nine patients (three females, six males; 30.9 ± 8.7 years, range = 15.5 – 42.1) with CF were
94 recruited from outpatient clinics at the Royal Devon and Exeter NHS Foundation Trust
95 Hospital. Participants were eligible to participate if they were ≥ 14 years of age and clinically
96 stable at the time of recruitment. To minimise impact upon usual clinical service, recruitment
97 was staggered over seven months (March – October 2017). Participant characteristics are listed
98 in Table 1.

99

100 *2.2. Ethics Approval*

101 All participants provided written informed consent (or assent, with parental consent where

102 applicable) upon enrolment. Ethics approval for this study was provided by an NHS Regional
103 Ethics Committee (Cornwall & Plymouth REC) and the Health Research Authority
104 (16/SW/0175).

105

106 *2.3. Timeline*

107 The period of investigation lasted 12-weeks, with a video-calling intervention occupying the
108 first 8-weeks, and a further 4-week observation period. Figure 1 details when measurements
109 associated with the study were taken, and when the intervention period occurred.

110

111 *2.4. Intervention*

112 All participants undertook 8-weeks of video-calls (Skype™, Microsoft, Luxembourg),
113 supervised by the same exercise therapist, receiving up to 3 supervised exercise sessions per
114 week.

115

116 Skype was chosen as it was freely available for all participants and provided secure end-to-end
117 encryption (therefore falling in line with hospital requirements for computer software). All
118 exercise sessions were booked as per any regular outpatient appointment, being pre-arranged
119 between participant and therapist at convenient times for both parties, provided these were a)
120 within working hours for the therapist (0800 – 1700) for security and safety reasons, and b) the
121 gymnasium facility was available. All sessions were placed upon the hospital ‘Patient
122 Administration System [PAS]’ as per usual clinical appointments. For the exercise therapist,
123 sessions were delivered on a laptop connected to the hospital Wi-Fi network, in a small
124 gymnasium on an outpatient therapy ward that could be booked by any staff member within
125 the ‘Therapy Services’ division of the hospital trust.

126

127 Exercise sessions were intended to be 30 minutes in duration, as per national PA guidelines
128 (3). All sessions were undertaken in participants own home, on a one-to-one basis with the
129 exercise therapist. Content of each session was personalised to each participant for the purposes
130 of this study, dependent on equipment available in participants homes. Some participants
131 utilised equipment such as bikes and treadmills, with others using free-weights, resistance-
132 bands or body-weight exercises. The frequency, intensity and timings of exercises throughout
133 the sessions were aligned with participants own preferences and capabilities, although a broad
134 ‘interval’ approach to exercises was adopted as this has shown to be beneficial to individual
135 with CF (15), and provides regular breaks for individuals to recover.

136

137 *2.5. Anthropometric and Pulmonary Measures*

138 Stature was measured to the nearest 0.1 cm (Holtain stadiometer, Crymych, UK) and body
139 mass to the nearest 0.1 kg (Seca, Birmingham, UK), with body-mass index (BMI) subsequently
140 calculated. Body-fat percentage (and subsequent fat-free mass) was identified using bio-
141 electrical impedance (Quadscan 4000; Bodystat, Douglas, Isle of Man). Estimates of arterial
142 blood oxygenation (SaO₂) were recorded using a pulse-oximeter (Nellcor; Medtronic,
143 Minneapolis, USA). Measures of forced expiratory volume in one-second (FEV₁), forced vital
144 capacity (FVC) were obtained using a spirometer (Vitalograph Alpha; Vitalograph,
145 Buckingham, UK and COPD-6, Vitalograph, Buckingham, UK) and normalised to percentage
146 of their predicted value (16).

147

148 *2.6. Physical Activity Measurement*

149 PA was recorded for 7 days at each time point (baseline, 4, 8, 12 weeks), using an accelerometer
150 (GENEActiv; ActivInsights, Kimbolton, UK) worn on the participants non-dominant wrist.
151 Participants were asked to wear it during all waking hours and complete an activity log to

152 qualitatively describe activity undertaken. Data was analysed in 60-second epochs, using pre-
153 validated cut points (17, 18) and data from at least two days with ten hours each (19) was
154 included for analyses to determine time spent (in minutes, and as percentage of wear time) in
155 sedentary, light, moderate and vigorous PA domains.

156

157 *2.7. Quality of Life*

158 QoL was assessed using the CF Questionnaire-Revised (CFQ-R) (20), providing an indication
159 of QoL across a range of domains. A value of 100 represents an optimal score.

160

161 *2.8. Assessment of Feasibility*

162 Feasibility and satisfaction of using video-calling was assessed at 8-weeks using a feedback
163 questionnaire developed in conjunction with the local Research and Development team for the
164 hospital trust (Supplement 1). To determine feasibility, guidelines set by Bowen *et al.* (21)
165 were utilised. Primary areas of evaluation for this particular intervention were demand,
166 implementation (study and session completion), practicality (technical issues) and acceptability
167 (participant feedback). Furthermore, analysis of anthropometric, pulmonary, PA and quality of
168 life (QoL) variables (described below) was purely descriptive in nature, with means and
169 standard deviations reported for each variable, but no formal statistical procedures taking place
170 (due to the feasibility nature of the study and insufficient statistical power).

171

172 **3. RESULTS**

173 *3.1. Demand*

174 Of the nine participants who undertook exercise sessions, two failed to complete the study.
175 Both participants were male (42 years, BMI 27.8 kg·m⁻², FEV₁ 59%_{Predicted} and 26 years, BMI
176 24.2 kg·m⁻², FEV₁ 23%_{Predicted}) and withdrew due to time constraints, one prior to their first

177 scheduled exercise session, and one after their first week of the intervention. In contrast, three
178 participants requested to continue delivery of exercise sessions beyond the scheduled study.
179 These participants commenced additional sessions as part of routine clinical care following the
180 one-month follow up observations. No adverse events related to exercise during the study were
181 reported by either participants, nor the exercise therapist delivering the intervention.

182

183 *3.2. Acceptability of Intervention*

184 Of the participants to undertake exercise sessions, compliance was variable. A total of 88
185 sessions were booked with participants, with 59 being attended by participants. Individual
186 compliance varied from 3/9 sessions (33%) to 10/10 sessions (100%) (mean = 68%). Of the 29
187 sessions not attended, reasons included: illness ($n = 13$ [45%]; including 9 missed by one
188 participant's exacerbation leading to admission); work-related commitments ($n = 8$; 28%),
189 school-related commitments ($n = 2$; 7%), unexplained non-attendance ($n = 2$; 7%), transport
190 (to home) issues ($n = 2$; 7%), participant cancellation ($n = 1$; 3%) and vacation ($n = 1$; 3%).

191

192 Of the training sessions completed, duration ranged from 12 – 29 minutes (mean = 20 minutes).
193 Sessions fell short of the desired 30 minutes in duration, due to both clinical restraints (e.g.
194 gymnasium bookings, staffing requirements) and participant preferences for shorter sessions.
195 Total contact time between therapist and participants for the 59 attended sessions equalled 18
196 hours and 21 minutes.

197

198 *3.3. Implementation*

199 Of the seven participants to complete the post-intervention feedback questionnaire, four had
200 used video-calling software previously: Skype ($n = 2$; 29%); Business Skype ($n = 1$; 14%);
201 iPhone Facetime ($n = 1$; 14%); with three participants (43%) using it for the first time due to

202 this study. Six of seven participants (86%) reported it was ‘easy’ to set up Skype, with one
203 (14%) reporting set up as ‘OK’.

204

205 Participants used differing devices to connect via Skype including laptop ($n = 4$; 57%),
206 smartphone ($n = 2$; 29%) and tablet ($n = 1$; 14%). Connections were made over Wi-Fi ($n = 4$;
207 57%), broadband ($n = 2$; 29%) and fibre broadband ($n = 1$; 14%), with four participants (57%)
208 reporting connection issues. These issues were experienced on differing devices and types of
209 connection (tablet/Wi-Fi, $n = 1$ [14%]; laptop/broadband, $n = 1$ [14%]; smartphone/Wi-Fi, $n =$
210 1 [14%]; laptop/fibre broadband, $n = 1$ [14%]). Sound quality was rated ‘good’ by 3/7 (43%)
211 participants and ‘OK’ by 4/7 (57%) participants. Video quality was rated ‘good’ by 4/7 (57%)
212 participants and ‘OK’ by 3/7 (43%) participants.

213

214 A total of 22 technical issues were reported by staff administering the intervention, for 15/59
215 (25%) sessions. As a proportion of the number of issues, these included connection issues ($n =$
216 8; 36%); delays/lags ($n = 7$; 32%); as well as visual ($n = 4$; 18%) and sound ($n = 3$; 14%)
217 problems. Technical issues resulted in three video-calls (5% of total) being cancelled.

218

219 *3.4. Participant Feedback*

220 Participants found using Skype for exercise useful, with ratings ranging from 7/10 – 10/10
221 (mean = 9/10). Overall satisfaction ratings, with regards to taking part in this research study,
222 included: ‘excellent’ ($n = 2$; 29%), ‘very good’ ($n = 3$; 43%) and ‘good’ ($n = 2$; 29%). All
223 participants (7/7; 100%) stated they would be happy to take part in future research studies.

224

225 Four participants provided qualitative feedback via the intervention feedback questionnaire.
226 These comments covered different topics, including their support for, and enjoyment of, the

227 exercise intervention:

228

229 [exercise at home] ...*saved me a lot of hassle, not having to travel up to the hospital for*

230 *exercise* (Participant 1)

231

232 *Really enjoyable & set me up for the day* (Participant 4)

233

234 *I found the Skype session useful* (Participant 7)

235

236 Participants also commented on the use of Skype as the modality of delivering the intervention,

237 with both positive and negative comments:

238

239 *Connection was sometimes poor and a slight delay - was sometimes difficult hearing my*

240 *physio* (Participant 1)

241

242 *Very easy to setup and use. The connection was very good at all times* (Participant 7)

243

244 Comments also highlighted how the disease interfered with the delivery of the intervention:

245

246 *Unfortunately, I was poorly for a couple of weeks so I didn't get to exercise as much as I*

247 *would have liked to* (Participant 1)

248

249 Finally, participants also provided suggestions for further enhancements of the study design,

250 with specific mention of timeline of events:

251

252 *Would be good to have a tailored timetable at the start detailing when each part is happening*
253 *e.g. Week 1: Exercise session x2; Week 2: wear exercise watch; Week 3: Review in hospital*
254 *etc. (Participant 9)*

255

256 *3.5. Participant Outcomes*

257 Participant characteristics are listed in Table 1, with subsequent changes in body size and lung
258 function, PA and QoL included in Tables 1, 2 and 3 respectively. The study was not powered
259 to detect changes in these outcomes and no changes were seen across all variables during the
260 course of the study.

261

262 The majority of data was collected at each visit without issue. However, of the seven
263 participants providing follow up data, one did not undertake body composition at 8-weeks, and
264 three SaO₂ measures (one at 8-weeks, 2 at 12-weeks) were missed; all due to non-availability
265 of equipment. Furthermore, for PA data, of the seven participants providing follow up data,
266 seven (of 21; 33%) PA measures across the three time points (4, 8, 12 weeks) were missed.
267 These seven missed measurements were due to one participant not wearing the accelerometer
268 (i.e. non-compliance, $n = 3$; 43%), and the remaining four due to equipment error ($n = 2$; 29%),
269 inpatient admission ($n = 1$; 14%) and loss within the postal service when returning
270 accelerometer to study team ($n = 1$; 14%).

271

272

273 **4. DISCUSSION**

274 The purpose of this study was to assess the feasibility and acceptability of using video-calling
275 technology to implement exercise programmes to engage patients with CF in exercise training.
276 Results suggest this modality may be feasible in practice, as it was accepted by participants

277 and could therefore potentially be used in clinical practice to deliver exercise interventions.
278 Many different aspects of feasibility can be assessed to evaluate new interventions, and this
279 study focused on the demand, implementation, practicality and acceptability (21).

280

281 *4.1. Demand and Implementation*

282 For assessment of demand and implementation, outcomes of interest include the actual use of
283 the programme and the degree of execution – characterised by the number of participants to
284 complete the study and number of sessions completed.

285

286 As with any exercise intervention, a loss of study participants is to be expected, and the
287 withdrawal of two participants (22%) in the present study is comparable to previous training
288 interventions in people with CF, both in terms of percentage of participants (4/18; 22% (22))
289 and absolute numbers (13). Therefore, given the self-reported reasons of ‘time commitments’
290 from participants as reasons for withdrawal, and comparable attrition rates to other studies, it
291 can be concluded that use of Skype itself is not a contributory factor in withdrawing from this
292 intervention – a reason for withdrawal that has been previously reported in people with chronic
293 obstructive pulmonary disease (COPD) (23).

294

295 In addition to withdrawals, 32% of appointments were missed by remaining participants for
296 various reasons, a lower rate than that seen when using Skype to deliver exercise for chronic
297 knee pain (24). These reasons were related to lifestyle and environmental factors that could
298 feasibly interfere with any intervention (e.g. work commitments) and were not related to the
299 use of Skype or the internet itself. This provides further evidence that the use of a Skype is a
300 feasible platform for use when remotely delivering an exercise intervention.

301

302 4.2. *Practicality*

303 In order to assess practicality, the ability of participants to carry out the intervention must be
304 considered. Within this study, there were multiple technical issues associated with using Skype,
305 such as connection issues and audio/visual problems. However, these issues were not mutually
306 exclusive and multiple issues could (and did) occur per video-contact session, thus reducing
307 the total number of affected sessions. The 25% of sessions that were affected is a lower rate to
308 that previously reported for an online Yoga intervention for people with COPD and heart
309 failure (25), although the issues are similar (e.g. visual lags).

310
311 Individual participants used varying platforms, and connection modalities, to operate Skype
312 and yet all participants reported at least one technical issue. Therefore, no single connection
313 mode or user platform can be associated with technical issues. Furthermore, as only 5% of calls
314 were cancelled as a result of technical issues, this suggests that use of Skype as a delivery
315 modality for exercise sessions is practically feasible. This is supported by previous use of
316 telemedicine in CF in the United Kingdom (UK), whereby connection problems have delayed
317 delivery of the intervention, but do not appear to have negatively affected the acceptability of
318 remote monitoring (26). Given the increased government investment in internet infrastructure
319 in the UK (27), it is likely such technical issues associated with video-calling will reduce in the
320 future, further increasing the feasibility of this intervention modality.

321
322 In addition to patients, interventions must also be practically feasible for clinical staff. This
323 current intervention required a total contact time of 18 hours and 21 minutes from the exercise
324 therapist, although this does not include clinical time associated with setting up appointments
325 or preparing programmes for delivery. However, the online nature of sessions does mean that
326 staff can contact patients immediately one after another (as done multiple times in the present

327 study), reducing the time normally required between meeting patients in the same facility due
328 to cross-infection risks. This can therefore be viewed as an efficient use of clinical time and
329 increases the practical feasibility of using Skype as a modality for exercise delivery.

330

331 *4.3. Acceptability*

332 Whilst the use of Skype does not appear to be a barrier to participation in an exercise training
333 programme, participant support and enjoyment is fundamentally required for an intervention
334 to be deemed acceptable. Without this participant support, any prospective development of an
335 intervention is unlikely to succeed in the long-term.

336

337 Participant feedback was largely positive in this study, with all participants who completed this
338 study being satisfied with the study and reporting Skype as a useful platform. Furthermore,
339 given that three participants requested to continue training sessions via Skype following the
340 intervention, this suggests acceptability of this modality. Qualitative comments were mixed;
341 although negative comments were related to technical issues associated with connection (which
342 could be overcome with advancements/upgrades in software/internet speeds), as opposed to
343 the use of an online platform and the burden of the disease itself. Positive responses to the
344 intervention are in agreement with previous studies to utilise Skype in CF (28), osteoarthritis
345 (29) and breast cancer (30).

346

347 *4.4. Anthropometrics, Pulmonary Function, PA and QoL*

348 As this study was not powered or designed to identify changes in function over time, analysis
349 of data is limited to descriptive statistics only. However, the majority of measures were
350 collected without issue, with the technical issues and loss within the postal system having been
351 experienced by other studies previously (31). Furthermore, the purpose of the study was to

352 remotely *supervise* exercise, not to remotely *monitor* exercise responses and as such, the loss
353 of data impacts only upon our understanding of habitual PA and does not impact upon clinical
354 decisions that may be made on account of monitoring, as incorporated into other prospective
355 monitoring interventions (32).

356

357 When examining the data obtained from the study, mean values for all anthropometric,
358 pulmonary, PA and QoL factors appear to have remained stable, suggesting maintenance of
359 function when engaging in an online exercise regimen over a 12-week period. The wide
360 standard deviation associated with each variable is likely due to a) the range of disease severity
361 within the recruited group (as shown by baseline FEV₁ ranging from 23 – 121% predicted [data
362 not reported]), and b) admissions to hospital due to pulmonary exacerbations experienced by
363 participants. Regardless, the lack of an overall decline in function aligns with previous studies
364 in other clinical groups that have utilised Skype to remotely deliver exercise interventions, such
365 as COPD (23), breast cancer (30) and chronic knee pain (24), all of which have found positive
366 outcomes associated with online-delivered exercise.

367

368 As patients with CF are recommended to undertake PA as part of disease management (3), the
369 challenge for clinical staff is how to implement this on a personalised level, and ensure
370 compliance. Whilst the mean duration of exercise sessions in this study was 20 minutes, below
371 the 30 minutes of recommended daily PA (3), it has been shown that accumulation of bouts of
372 as little as 10 minutes of MVPA could yield long-term benefits in CF (33). Therefore, use of
373 telehealth could prove to be an integral component of future care and possibly reduce the time
374 required on behalf of clinical teams to engage patients in exercise and PA.

375

376 The findings of the present study have implications for clinical practice, by identifying issues
377 associated with a platform that has the potential to overcome geographical barriers and reduce
378 cross-infection risks.

379

380 *4.5. Study Limitations*

381 The small samples size (due to the feasibility driven approach of this investigation) will limit
382 the utility of findings to further groups of individuals with CF, although the findings can be
383 used to statistically power future studies. Furthermore, the variances in the types of exercise
384 undertaken by each participant has the potential to bias results. Whilst a uniform training
385 regimen would alleviate such bias, it would remove the personalised approach to each training
386 regimen that can improve acceptance and adherence. This therefore, provides a challenge for
387 future researchers to accommodate this trade-off between uniform and personalised approaches
388 to exercise prescription.

389

390 In conclusion, this feasibility study demonstrated that use of Skype as a telehealth platform can
391 be successfully used to engage patients with CF in a personalised exercise regimen, and that
392 the participants in this study responded positively to this approach. Future research is warranted
393 to identify whether the utility of this delivery modality can effectively improve health and
394 physical function in CF.

395

396 **ACKNOWLEDGEMENTS**

397 The authors express their gratitude towards the participants who have volunteered their time
398 for this study, as well as the Cystic Fibrosis Multi-Disciplinary Team at the Royal Devon &
399 Exeter NHS Foundation Trust Hospital.

400

401 **FUNDING**

402 This feasibility study was funded by a small grants fund from the Royal Devon & Exeter NHS
403 Foundation Trust Hospital.

404

405 **REFERENCES**

406 1. Hebestreit H, Kieser S, Rüdiger S, Schenk T, Junge S, Hebestreit A, et al. Physical
407 activity is independently related to aerobic capacity in cystic fibrosis. *European Respiratory*
408 *Journal*. 2006;28(4):734-9.

409 2. Schneiderman JE, Wilkes DL, Atenafu EG, Nguyen T, Wells GD, Alarie N, et al.
410 Longitudinal relationship between physical activity and lung health in patients with cystic
411 fibrosis. *European Respiratory Journal*. 2014;43(3):817-23.

412 3. Cystic Fibrosis Trust. Standards of care and good clinical practice for the physiotherapy
413 management of cystic fibrosis. London, UK; 2017.

414 4. Abbott J, Dodd M, Bilton D, Webb AK. Treatment compliance in adults with cystic
415 fibrosis. *Thorax*. 1994;49(2):115-20.

416 5. Prasad SA, Cerny FJ. Factors that influence adherence to exercise and their
417 effectiveness: Application to cystic fibrosis. *Pediatric Pulmonology*. 2002;34(1):66-72.

418 6. Tenforde AS, Hefner JE, Kodish-Wachs JE, Iaccarino MA, Paganoni S. Telehealth in
419 *Physical Medicine and Rehabilitation: A Narrative Review*. *PM&R*. 2017;9(5S):S51-S8.

420 7. Wood J, Mulrennan S, Hill K, Cecins N, Morey S, Jenkins S. Telehealth clinics increase
421 access to care for adults with cystic fibrosis living in rural and remote Western Australia.
422 *Journal of Telemedicine and Telecare*. 2017;23(7):673-9.

423 8. Tagliente I, Trieste L, Solvoll T, Murgia F, Bella S. Telemonitoring in Cystic Fibrosis:
424 A 4-year Assessment and Simulation for the Next 6 Years. *Interactive Journal of Medical*
425 *Research*. 2016;5(2):e11.

- 426 9. Jain M, Saiman LM, Sabadosa K, LiPuma JJ. Point: Does the risk of cross infection
427 warrant exclusion of adults with cystic fibrosis from cystic fibrosis foundation events? Yes.
428 Chest. 2014;145(4):678-80.
- 429 10. Cox NS, Alison JA, Rasekaba T, Holland AE. Telehealth in cystic fibrosis: a systematic
430 review. Journal of Telemedicine and Telecare. 2012;18(2):72-8.
- 431 11. Cox NS, Alison JA, Button BM, Wilson JW, Holland AE. Feasibility and acceptability
432 of an internet-based program to promote physical activity in adults with cystic fibrosis.
433 Respiratory Care. 2015;60(3):422-9.
- 434 12. Cox NS, Alison JA, Button BM, Wilson JW, Holland AE. Assessing exercise capacity
435 using telehealth: a feasibility study in adults with cystic fibrosis. Respir Care. 2013;58(2):286-
436 90.
- 437 13. Kriemler S, Kieser S, Junge S, Ballmann M, Hebestreit A, Schindler C, et al. Effect of
438 supervised training on FEV1 in cystic fibrosis: a randomised controlled trial. Journal of Cystic
439 Fibrosis. 2013;12(6):714-20.
- 440 14. Schneiderman-Walker J, Pollock SL, Corey M, Wilkes DD, Canny GJ, Pedder L, et al.
441 A randomized controlled trial of a 3-year home exercise program in cystic fibrosis. The Journal
442 of Pediatrics. 2000;136(3):304-10.
- 443 15. Gruber W, Orenstein DM, Braumann KM, Beneke R. Interval exercise training in cystic
444 fibrosis - effects on exercise capacity in severely affected adults. Journal of Cystic Fibrosis.
445 2014;13(1):86-91.
- 446 16. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung
447 volumes and forced ventilatory flows. European Respiratory Journal. 1993;6 Suppl 16:5-40.
- 448 17. Esliger DW, Rowlands AV, Hurst TL, Catt M, Murray P, Eston RG. Validation of the
449 GENE Accelerometer. Medicine and Science in Sports and Exercise. 2011;43(6):1085-93.

- 450 18. Phillips LR, Parfitt G, Rowlands AV. Calibration of the GENEActiv accelerometer for
451 assessment of physical activity intensity in children. *Journal of Science and Medicine in Sport*.
452 2013;16(2):124-8.
- 453 19. Rich C, Geraci M, Griffiths L, Sera F, Dezateux C, Cortina-Borja M. Quality control
454 methods in accelerometer data processing: defining minimum wear time. *PLoS One*.
455 2013;8(6):e67206.
- 456 20. Quittner AL, Sawicki GS, McMullen A, Rasouliyan L, Pasta DJ, Yegin A, et al.
457 Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample.
458 *Quality of Life Research*. 2012;21(7):1267-78.
- 459 21. Bowen DJ, Kreuter M, Spring B, Cofta-Woerpel L, Linnan L, Weiner D, et al. How we
460 design feasibility studies. *American Journal of Preventive Medicine*. 2009;36(5):452-7.
- 461 22. Beaudoin N, Bouvet GF, Coriati A, Rabasa-Lhoret R, Berthiaume Y. Combined
462 exercise training improves glycemic control in adult with cystic fibrosis. *Medicine and Science
463 in Sports and Exercise*. 2017;49(2):231-7.
- 464 23. Nield M, Hoo GW. Real-time telehealth for COPD self-management using Skype.
465 *COPD: Journal of Chronic Obstructive Pulmonary Disease*. 2012;9(6):611-9.
- 466 24. Bennell KL, Nelligan R, Dobson F, Rini C, Keefe F, Kasza J, et al. Effectiveness of an
467 Internet-Delivered Exercise and Pain-Coping Skills Training Intervention for Persons With
468 Chronic Knee Pain: A Randomized Trial. *Annals of Internal Medicine*. 2017;166(7):453-62.
- 469 25. Donesky D, Selman L, McDermott K, Citron T, Howie-Esquivel J. Evaluation of the
470 Feasibility of a Home-Based TeleYoga Intervention in Participants with Both Chronic
471 Obstructive Pulmonary Disease and Heart Failure. *Journal of Alternative and Complementary
472 Medicine*. 2017;23(9):713-21.

- 473 26. Wilkinson OM, Duncan-Skingle F, Pryor JA, Hodson ME. A feasibility study of home
474 telemedicine for patients with cystic fibrosis awaiting transplantation. *Journal of Telemedicine*
475 *and Telecare*. 2008;14(4):182-5.
- 476 27. UK Government. *UK Digital Strategy 2017*. 1. Connectivity - building world-class
477 digital infrastructure for the UK. London: Department for Digital, Culture, Media & Sport;
478 2017.
- 479 28. Gur M, Nir V, Teleshov A, Bar-Yoseph R, Manor E, Diab G, et al. The use of telehealth
480 (text messaging and video communications) in patients with cystic fibrosis: A pilot study.
481 *Journal of Telemedicine and Telecare*. 2017;23(4):489-93.
- 482 29. Hinman RS, Nelligan RK, Bennell KL, Delany C. "Sounds a bit crazy, but it was almost
483 more personal": A qualitative study of patient and clinician experiences of physical therapist-
484 prescribed exercise for knee osteoarthritis via Skype. *Arthritis Care and Research*. 2017.
- 485 30. Galiano-Castillo N, Cantarero-Villanueva I, Fernandez-Lao C, Ariza-Garcia A, Diaz-
486 Rodriguez L, Del-Moral-Avila R, et al. Telehealth system: A randomized controlled trial
487 evaluating the impact of an internet-based exercise intervention on quality of life, pain, muscle
488 strength, and fatigue in breast cancer survivors. *Cancer*. 2016;122(20):3166-74.
- 489 31. Sabia S, van Hees VT, Shipley MJ, Trenell MI, Hagger-Johnson G, Elbaz A, et al.
490 Association between questionnaire- and accelerometer-assessed physical activity: the role of
491 sociodemographic factors. *American Journal of Epidemiology*. 2014;179(6):781-90.
- 492 32. Choyce J, Shaw KL, Sitch AJ, Mistry H, Whitehouse JL, Nash EF. A prospective pilot
493 study of home monitoring in adults with cystic fibrosis (HOME-CF): protocol for a randomised
494 controlled trial. *BMC Pulmonary Medicine*. 2017;17(1):22.
- 495 33. Cox NS, Alison JA, Button BM, Wilson JW, Morton JM, Holland AE. Accumulating
496 physical activity in at least 10-minute bouts predicts better lung function after 3-years in adults
497 with cystic fibrosis. *ERJ Open Research*. 2018;4(2).

498 **Table 1.** Changes in anthropometric and pulmonary variables over the course of the study
 499 period.

| | Baseline (0 weeks) | Intervention End (8 weeks) | Follow Up (12 weeks) |
|--|----------------------------------|-------------------------------|-------------------------|
| | <i>n</i> = 7 | <i>n</i> = 7 | <i>n</i> = 7 |
| Age (years) | 30.0 (8.6) | 30.2 (8.6) | 30.3 (8.6) |
| Height (m) | 1.64 (0.09) | 1.64 (0.09) | 1.64 (0.09) |
| Weight (kg) | 61.9 (14.8) | 62.2 (14.2) | 62.8 (14.7) |
| BMI (kg·m ⁻²) | 22.8 (3.7) | 23.0 (3.6) | 23.1 (3.6) |
| Fat Mass (kg) | 13.2 (6.3) | 14.0 (6.5) | 13.4 (6.7) |
| Fat Mass (%) | 20.8 (9.2) | 21.1 (8.0) | 21.1 (9.7) |
| Fat Free Mass (kg) | 48.7 (11.4) | 50.8 (11.0) | 49.4 (12.5) |
| Fat Free Mass (%) | 79.2 (9.2) | 78.9 (8.0) | 78.9 (9.7) |
| Resting SaO ₂ (%) | 97 (1) | 97 (2) | 98 (1) |
| FEV ₁ (L) | 2.53 (1.47) | 2.51 (1.55) | 2.54 (1.43) |
| FEV ₁ (% _{Predicted}) | 74 (31) | 73 (34) | 73 (32) |
| FVC (L) ^a | 3.65 (1.68) | 3.61 (1.71) | 3.58 (1.49) |
| FVC (% _{Predicted}) ^a | 93 (25) | 91 (27) | 90 (22) |
| Homozygous ΔF508 | | 3 | |
| Heterozygous ΔF508 | | 4 | |
| Other Alleles | E1371X, Q220X, 2789+5G>A, D1152H | | |

500 All values reported as mean (SD). BMI, body mass index; FEV₁, forced expiratory volume in
 501 1 second; FVC, forced vital capacity. Data presented for *n* = 7 to demonstrate the seven
 502 participants who completed the study. a: FVC only available for 6/7 participants due to positive
 503 screen of non-tuberculosis mycobacterium in one participant, whereby subsequent use of
 504 personal spirometer only provides FEV₆, not FVC.

505
 506
 507
 508
 509
 510
 511

512 **Table 2.** Changes in physical activity over the course of the study period.

| | Baseline (0 weeks) | Mid-Intervention (4 weeks) | Intervention End (8 weeks) | Follow Up (12 weeks) |
|-------------------------------------|---------------------------|-------------------------------|-------------------------------|---------------------------|
| Activity Domain | <i>n</i> = 6 ^a | <i>n</i> = 4 ^b | <i>n</i> = 6 ^c | <i>n</i> = 4 ^d |
| Sedentary (mins·day ⁻¹) | 528 (86) | 565 (61) | 470 (66) | 513 (151) |
| Sedentary (%) | 65 (8) | 67 (13) | 65 (12) | 63 (20) |
| Light (mins·day ⁻¹) | 96 (20) | 85 (6) | 86 (40) | 98 (33) |
| Light (%) | 12 (3) | 10 (1) | 14 (9) | 13 (4) |
| Moderate (mins·day ⁻¹) | 180 (72) | 201 (129) | 193 (104) | 196 (148) |
| Moderate (%) | 22 (7) | 23 (13) | 24 (10) | 24 (16) |
| Vigorous (mins·day ⁻¹) | 5 (5) | 6 (8) | 4 (4) | 2 (3) |
| Vigorous (%) | 1 (1) | 1 (1) | 1 (1) | 0 (0) |

513 All values are presented as means (SD). a: Baseline values for six participants, accounting for
514 all individuals to complete study (*n* = 7), and loss of data due to non-wear of accelerometer (*n*
515 = 1). b: 4-weeks only includes four participants due to withdrawal (*n* = 2), non-wear of
516 accelerometer (*n* = 1), inpatient admission unrelated to interventions (*n* = 1), and loss of
517 accelerometer within postal system (*n* = 1). c: 8-weeks only includes six participants due to
518 withdrawal (*n* = 2) and non-wear of accelerometer (*n* = 1). d: 12-weeks only includes four
519 participants due to withdrawal (*n* = 2), equipment error (*n* = 2), and non-wear of accelerometer
520 (*n* = 1).

521
522
523
524
525
526
527
528
529
530

531 **Table 3.** Changes in quality of life (QoL) over the course of the study period.

| | Baseline (0 weeks) | Intervention End (8 weeks) | Follow Up (12 weeks) |
|-------------------|---------------------------|-------------------------------|---------------------------|
| QoL Dimension | <i>n</i> = 6 ^a | <i>n</i> = 6 ^b | <i>n</i> = 7 ^c |
| Physical | 72 (34) | 58 (37) | 72 (33) |
| Vitality | 56 (25) | 51 (21) | 56 (24) |
| Emotion | 71 (27) | 71 (18) | 79 (18) |
| Eating | 80 (25) | 83 (18) | 88 (17) |
| Treatment Burden | 56 (36) | 37 (24) | 49 (33) |
| Health Perception | 70 (24) | 37 (38) | 52 (34) |
| Social | 74 (16) | 62 (19) | 62 (29) |
| Body Image | 69 (29) | 69 (28) | 73 (27) |
| Role | 75 (27) | 65 (38) | 77 (28) |
| Weight | 67 (42) | 67 (30) | 71 (36) |
| Respiratory | 52 (33) | 56 (23) | 64 (27) |
| Digestive | 85 (22) | 91 (11) | 87 (20) |

532 All values are presented as means (SD). a: Baseline values for six participants, accounting for
 533 all individuals to complete study (*n* = 7), but failure of one participant to complete baseline
 534 QoL (*n* = 1). b: 8-weeks only includes six participants due to withdrawal from study (*n* = 2)
 535 and loss of QoL questionnaire within postal system (*n* = 1). c: 12-weeks only includes seven
 536 participants due to withdrawal from study (*n* = 2).

537
 538
 539
 540
 541
 542
 543
 544
 545
 546
 547
 548

549 **Figure 1.** Schematic representation of assessment and intervention time points.

550

551

552

553

554

555

556

557

558

559


560

561

562

563

564



562 **SUPPLEMENTARY FILES**

563 Supplement 1. Study feedback questionnaire administered to participants, following 8-week
564 intervention.

SKYPE STUDY FEEDBACK QUESTIONNAIRE.

Thank you for taking part in this Research Study at the RD&E. We would be grateful if you would complete this questionnaire about your experience as a Research participant so that we can improve the service we provide.

The information you provide will be collected by the Research and Development team and will be treated in the strictest confidence. It will not affect any further treatment or participation in a Research Study.

Thank you.

| | | | | |
|---|-------------------------------------|------------------------------------|---------------------------------------|--|
| <u>About Skype.</u> | | | | |
| Did you use Skype or similar software before now? | <input type="checkbox"/> YES | <input type="checkbox"/> NO | | |
| If YES please state which software you used: | | | | |
| How easy/difficult was it to set up Skype? | <input type="checkbox"/> EASY | <input type="checkbox"/> OK | <input type="checkbox"/> DIFFICULT | |
| Which (if any) issues did you encounter? | | | | |
| What device are you using for Skype? | <input type="checkbox"/> DESKTOP | <input type="checkbox"/> LAPTOP | <input type="checkbox"/> TABLET | <input type="checkbox"/> SMARTPHONE |
| Have you had any connection issues? | | | <input type="checkbox"/> YES | <input type="checkbox"/> NO |
| What internet connection are you using? | <input type="checkbox"/> 3G | <input type="checkbox"/> 4G | <input type="checkbox"/> BROADBAND | <input type="checkbox"/> FIBREBROADBAND |
| How was the sound quality? | | <input type="checkbox"/> GOOD | <input type="checkbox"/> OK | <input type="checkbox"/> BAD |
| How was the video quality? | | <input type="checkbox"/> GOOD | <input type="checkbox"/> OK | <input type="checkbox"/> BAD |
| Did you find using Skype for an exercise session useful? | | | | |
| Not at all 1 2 3 4 5 6 7 8 9 10 very useful | | | | |
| How could this format of appointment be improved? | | | | |
| Overall comments/opinions: | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

| <u>About the Study.</u> | | YES | PARTLY | NO | | | | | |
|--|----------------|--------------------------|----------------------------------|--------------------------|--------------------------|--------------------------|-------|-------|-----|
| Was the study information sheet easy to understand? | | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | |
| Did the Research Team answer questions about the study in a way that you could understand? | | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | |
| Did you know what was expected of you when you agreed to take part in the study? | | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | |
| Do you feel it is important to take part in Research? | | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | |
| Would you be happy to take part in another Research Study? | | <input type="checkbox"/> | | <input type="checkbox"/> | | | | | |
| <u>General Satisfaction.</u> | | | | | | | | | |
| | | POOR | FAIR | GOOD | VERY GOOD | EXCELLENT | | | |
| My overall satisfaction with taking part in this Research Study is:- | | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | |
| <u>Please add any further comments about your experience of taking part in this study:-</u> | | | | | | | | | |
| _____ | | | | | | | | | |
| _____ | | | | | | | | | |
| <u>Please tell us your reasons for taking part in this study. Circle all the options which apply.</u> | | | | | | | | | |
| 1) To help others | 2) Own benefit | 3) Felt obliged | 4) Other – please specify: _____ | | | | | | |
| ADDITIONAL INFORMATION – PLEASE CIRCLE | | | | | | | | | |
| AGE GROUP | 11-16 | 17-21 | 22-30 | 31-40 | 41-50 | 51-60 | 61-70 | 71-80 | 80+ |
| Thank you for your help. | | | | | | | | | |
| RESEARCH TRIAL INFORMATION TO BE COMPLETED BY STUDY TEAM | | | | | | | | | |
| Study Title: | | | | | | R&D Number: | | | |